• The GR gene can be inactivated in Streptamer ® -selected CMV-specific CD8 + T cells using TALEN.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for high-risk hematological malignancies, including leukemias, lymphomas and myelodysplastic syndromes 1 . A number of factors influence clinical outcomes, including history of exposure to cytomegalovirus (CMV). Human CMV is a β -herpesvirus with a seroprevalence of 30-70% in developed countries. CMV infection after HSCT can cause multiple complications including gastroenteritis, pneumonitis, hepatitis, retinitis or encephalitis 2, 3 . Pneumonitis is the most serious manifestation with a mortality rate of over 80% without antiviral chemotherapy, and of over 50% even with standard antiviral therapies 4 .
Patients at the highest risk of clinically problematic CMV infection are serologically positive recipients [5] [6] [7] , recipients of T-cell-depleted grafts 8,9 and those receiving corticosteroids for the treatment of graft-versus-host disease (GvHD) post HSCT 10 .
Thus CMV infection occurs in 60-90% of CMV seropositive patients, dependent on whether T cell depletion is performed or not. Despite modern pre-emptive treatment strategies, potentially life threatening disease still occurs in 3-10% of hematopoietic stem cell transplant recipients 11 . Effective antiviral drug therapies are available, but their use is associated with renal toxicity, myelosuppression and, less commonly, the emergence of drug resistance [12] [13] [14] [15] . There is therefore an important clinical need for therapies that speed the tempo of immune reconstitution to reestablish immunologic control of the virus.
Because T-cell mediated immunity has been shown to play a critical role in the sustained control of CMV infection [16] [17] [18] , several groups have investigated strategies
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From to generate CMV-specific T lymphocytes for adoptive immunotherapy. These studies demonstrated that CMV-specific T cells can be expanded or directly selected from seropositive donors, administrated safely, and can restore functional T-cell immunity when the primary problem is numerical deficiency [19] [20] [21] [22] [23] [24] . Importantly, virus-specific T cells engrafted, expanded and conferred protective immunity despite therapeutic levels of calcineurin inhibitors (e.g. cyclosporine, tacrolimus), suggesting that these agents are permissive to the desired therapeutic activity. Parallel advances have been made in cases where the donor is CMV seronegative, either by expanding naïve CMV-reactive T cells or by the use of third party donor cells 25, 26 . From a global perspective, however, most recurrent and refractory CMV infections occur in patients with significant GvHD
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, largely as a result of high dose glucocorticoid therapy.
Despite advances in our understanding of the pathophysiology of GvHD, glucocorticoids remain the most effective and favored initial therapy for the treatment of both acute and chronic GvHD [27] [28] [29] . This provides a major obstacle to adoptive antiviral immunotherapy since glucocorticoids suppress T cell numbers and function.
Glucocorticoids exert potent immunosuppressive effects after binding to the glucocorticoid receptor (GR), a ligand-activated transcription factor 30 . Sequestered by a heat-shock protein complex (hsp90, hsp70, FK506 binding protein 52), the GR translocates to the nucleus upon binding to glucocorticoids 31 , where it exerts direct effects on gene expression (e.g., the induction of Annexin I and mitogen-activated protein kinases phosphatase 1) and indirect effects through interactions with other transcription factors (i.e., NF-κB and activator protein 1). Other evidence supports non-genomic mechanisms of action involving second-messenger cascades (e.g., the phosphatidylinositol-3-hydroxykinase (PI3K)-Akt-eNOS pathway) [32] [33] [34] . It is notable that the GR is essential for the immunosuppressive effects of glucocorticoids in T 34, 35 . Despite the wide range of gene targets for the GR, only a single GR gene has been described, which generates several GR isoforms via alternative splicing 36 . Based on these considerations, we hypothesized that selective inactivation of the GR gene in CMVspecific T cells would render them resistant to the suppressive effects of corticosteroids, thus providing a therapeutic option for the treatment of CMV infection in the context of glucocorticoid administration.
Powerful tools for genome editing are now available, including the Transcription Activator-Like (TAL) Effector Nucleases (TALEN) 37, 38 . TALEN are attractive reagents for therapeutic applications because of their high specificity, conferred by the long targeting domains (17 base-pair target sequence) and the requirement for homodimerization of the associated FokI domain-containing nucleases. The endonucleases cause site-specific double-stranded DNA breaks (DSB) and trigger natural DNA repair mechanisms, notably non-homologous end joining recombination (NEHJ) that is error prone. The introduction of insertions or deletions can then shift the reading frame and inactivate the gene function 39 . The success rate and activity of TALEN depends heavily on the cell type and delivery method 40 . Transfection by electroporation with mRNA is an attractive method for therapeutic application because of its reproducibility and cost effectiveness.
We developed a highly efficient TALEN pair, specific for the exon 2 sequence of the human GR gene. We demonstrated that following mRNA transfection, GR-targeting TALEN induce disruption of the GR gene at high frequencies of 55% and 60% in primary human T cells and the human HLA-A*02 T cell lymphoma (T2) line respectively. After dexamethasone selection, the enriched subset of CMV-specific T 
Methods

Cell culture and transfection
The HLA-A02 T2 lymphoma cell line was provided by Dr Martin Pule and maintained in RPMI-1640 supplemented with 10% Fetal Calf Serum (GIBCO), Lglutamine, Penicillin-Streptomycin (Sigma). CD8+T cells were selected by positive selection using human CD8 MicroBeads (Miltenyi) according to the manufacturer.
The cells were stimulated with Dynabeads Human T-Activator CD3/CD28
(Invitrogen) at 37°C in 5% CO2 at 1×10 6 cells/ml for 4 days. Cells were kept at 1×10 for the appearance of xeno-GVHD-like symptoms, including hair loss, hunched posture and reduced mobility.
For additional information, see supplemental data section
Results
Efficient inactivation of the GR in T2 cells after mRNA-mediated TALEN delivery
To inactivate the GR gene, 6 pairs of TALEN were designed to target different genomic sequences, corresponding to various domains of the GR protein (Table S1 ), without apparent cell toxicity
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TALEN-modified T2 cells are resistant to glucocorticoids
The T2 GR-Ex2 enriched population of cells and control wild type (T2 wt ) cells were incubated for 72 hours in vitro in the presence or absence of DEX (10 -4 M). Whilst 50% of the T2 wt cells were sensitive to DEX-induced apoptosis and secondary necrosis, the TALEN-modified T2 GR-Ex2 cells were DEX-resistant ( Fig. 2A, Fig. S1B ).
A dose-response cell death assay with DEX or prednisone (10
confirmed that the T2 GR-Ex2 cells were specifically resistant to both glucocorticoids (Fig. 2D) . These results
show a potential proof of concept for the rapid production of glucocorticoid-resistant T cells, using an optimized mRNA-electroporation protocol and TALEN.
TALEN-mediated GR inactivation in primary CMV specific-T cells
Clinical application of CMV-specific T cell therapies following HSCT requires selection or selective expansion of virus-specific T cells in order to limit the number of potentially alloreactive T cells that are transferred. The necessity to avoid infusing alloreactive T cells is even more pertinent in patients who already have GvHD.
Selection of CMV-specific T cells based on T cell receptor specificity using HLA- (Fig. 3A) .
Pp65-specific CD8 + T cells were subsequently expanded in vitro for one week and then electroporated with 20 μ g of GFP mRNA or 10μg of each half TALEN mRNA.
The optimized protocol provided both high viability (median >60%), and a very high transfection efficacy (median 98%), overcoming the frequently reported limitations (toxicity and low transfection efficacy) of primary T cell engineering (Fig. 3B) .
Miseq analysis of the targeted exon 2 sequence showed 55% NHEJ-mutagenesis 3 days after transfection with the mRNA TALENs and characterized the different deletions induced at the specific on-target site (35 insertions were also reported in the 6046 reads; data not shown) (Fig. 3C, Fig. S2A ). Analysis of the mutational rate by hours after transfection we observed a 50% decrease of GR protein expression and after 5 days of culture with DEX, no GR protein was detectable in the CMV GR-Ex2 cells by western blot (Fig. 3D, Fig. S2C ). In addition, the potential off-target sites of the GR-Ex2 TALEN in the human genome were characterized in silico and the 14 most likely off-target cleavage sites, conserved in the seed region and containing 7-8-base mismatches were ranked (Table S3 ). We measured the frequencies of small indels at the on-target site and putative off-target sites using deep sequencing. Insertion and deletion events frequencies at the 14 potential off-sites in the TALEN-treated cells (CMV GR-Ex2 cells) were identical to the ones observed in the mock-transfected cells CMV GR-Ex2 cells treated or not with DEX prior to and during the co-culture. The NLV-specific lytic activity of the CMV GR-Ex2 cells was comparable to that of the CMV wt cells, but was not affected by the DEX treatment in contrast to that of the CMV wt cells. High specific killing activity (60%) was maintained even at a 1:1 effector-target ratio (Fig. 4C, D) .
TALEN-modified CD8 +GR-Ex2 T cells are resistant to DEX in a xeno-GvHD model
To measure both glucocorticoid resistance and functional activity of polyclonal human CD8+T cells in vivo, 1x10 6 CD8 +wt or CD8 +GR-Ex2 T cells, generated as previously described, were injected intravenously into irradiated NSG mice treated or not with DEX for 21 days. These experiments also address a potential safety concern regarding the infusion of glucocorticoid-resistant alloreactive T cells. In humanmouse xenogeneic GvHD, human immune cell infiltration has been reported in peripheral tissues such as the skin [45] [46] [47] , mimicking the human form of the disease 48 .
In (Fig. 5A, Fig. S3 ). Extensive fibrosis and loss of normal splenic architecture, and the presence of a GZB + CD8 population were also documented in these 3 cohorts (Fig. 5B, Fig. S3D ). Human CD8 +GR-Ex2 and CD8 +wt T cells were selected from pooled-spleens using human anti-CD2 beads, analyzed for GR expression by western blot, and compared to CD8 +GR-Ex2 at day 3 following transfection with TALEN. GR expression analysis at day 3 demonstrated a 50% decrease of GR protein, whilst the CD8 +GR-Ex2 T cells engrafted in NSG mice treated with DEX or not did not express GR (Fig. 5C) . Overall, the results demonstrate the ability to render polyclonal T cell populations resistant to glucocorticoids in vivo, but also the need to ensure that clinical development focuses on generating highly pure populations of virus-specific T cells that are devoid of alloreactive potential for application in the transplant setting.
Discussion
We demonstrate efficient and rapid inactivation of the GR gene in CMV-specific T cells using electroporation of TALEN mRNA, leading to glucocorticoid resistance but retention of functionality in both in vitro assays and in vivo models. The processes described here are compatible with scaling to Current Good Manufacturing Practice . In all of these examples, GR-resistance would both protect adoptively transferred cells from the effects of glucocorticoids, and provide a selective survival advantage over endogenous T cells.
In conclusion, we show that glucocorticoid-resistant CMV-specific T cells can be rapidly generated in vitro using GR-TALEN and these GR-inactivated T cells Centres.
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